Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 57 entries
Sorted by: Best Match Show Resources per page
Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma.

HPB : the official journal of the International Hepato Pancreato Biliary Association

Wolkersdörfer GW, Thiede C, Fischer R, Ehninger G, Haag C.
PMID: 18333108
HPB (Oxford). 2007;9(1):16-25. doi: 10.1080/13651820600839555.

BACKGROUND: Current therapies for adenocarcinoma of the pancreas do not improve the life expectancy of patients.METHODS: In a non-randomized pilot trail we tested whether a local therapy based upon an adenoviral gene transfer of wild type p53 in combination...

Cite
Wolkersdörfer GW, Thiede C, Fischer R, et al. Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma. HPB (Oxford). 2007;9(1):16-25doi: 10.1080/13651820600839555.
Wolkersdörfer, G. W., Thiede, C., Fischer, R., Ehninger, G., & Haag, C. (2007). Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma. HPB : the official journal of the International Hepato Pancreato Biliary Association, 9(1), 16-25. https://doi.org/10.1080/13651820600839555
Wolkersdörfer, Gernot W, et al. "Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma." HPB : the official journal of the International Hepato Pancreato Biliary Association vol. 9,1 (2007): 16-25. doi: https://doi.org/10.1080/13651820600839555
Wolkersdörfer GW, Thiede C, Fischer R, Ehninger G, Haag C. Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma. HPB (Oxford). 2007;9(1):16-25. doi: 10.1080/13651820600839555. PMID: 18333108; PMCID: PMC2020772.
Copy Download .nbib Format: NLM
[Enzyme-pattern in the root-meristem].

Planta

Thielke C.
PMID: 24557787
Planta. 1966 Dec;68(4):371-4. doi: 10.1007/BF00386336.

In the meristem of growing roots a cell complex is marked by the Nadi-reaction which represents the zone of beginning differentiation.

Cite
Thielke C. Enzymmuster im Wurzelmeristem. [Enzyme-pattern in the root-meristem]. Planta. 1966;68(4):371-4doi: 10.1007/BF00386336.
Thielke, C. (1966). Enzymmuster im Wurzelmeristem. [Enzyme-pattern in the root-meristem]. Planta, 68(4), 371-4. https://doi.org/10.1007/BF00386336
Thielke, C. "Enzymmuster im Wurzelmeristem." [Enzyme-pattern in the root-meristem]. Planta vol. 68,4 (1966): 371-4. doi: https://doi.org/10.1007/BF00386336
Thielke C. Enzymmuster im Wurzelmeristem. [Enzyme-pattern in the root-meristem]. Planta. 1966 Dec;68(4):371-4. doi: 10.1007/BF00386336. German. PMID: 24557787.
Copy Download .nbib Format: NLM
Characterizing the Indigenous Forest Peoples of Latin America: Results from Census Data.

World development

Thiede BC, Gray C.
PMID: 32123463
World Dev. 2020 Jan;125. doi: 10.1016/j.worlddev.2019.104685. Epub 2019 Oct 11.

Indigenous populations in Latin America are central to regional and global efforts toward achieving socially and environmentally sustainable development. However, existing demographic research on indigenous forest peoples (IFPs) has many limitations, including a lack of comparable cross-national evidence. We...

Cite
Thiede BC, Gray C. Characterizing the Indigenous Forest Peoples of Latin America: Results from Census Data. World Dev. 2019;125doi: 10.1016/j.worlddev.2019.104685.
Thiede, B. C., & Gray, C. (2020). Characterizing the Indigenous Forest Peoples of Latin America: Results from Census Data. World development, 125. https://doi.org/10.1016/j.worlddev.2019.104685
Thiede, Brian C, and Gray, Clark. "Characterizing the Indigenous Forest Peoples of Latin America: Results from Census Data." World development vol. 125 (2020). doi: https://doi.org/10.1016/j.worlddev.2019.104685
Thiede BC, Gray C. Characterizing the Indigenous Forest Peoples of Latin America: Results from Census Data. World Dev. 2020 Jan;125. doi: 10.1016/j.worlddev.2019.104685. Epub 2019 Oct 11. PMID: 32123463; PMCID: PMC7051013.
Copy Download .nbib Format: NLM
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.

Leukemia

Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Döhner H, Thiede C, Döhner K.
PMID: 34316017
Leukemia. 2021 Jul 28; doi: 10.1038/s41375-021-01323-0. Epub 2021 Jul 28.

In acute myeloid leukemia (AML) internal tandem duplications of the FLT3 gene (FLT3-ITD) are associated with poor prognosis. Retrospectively, we investigated the prognostic and predictive impact of FLT3-ITD insertion site (IS) in 452 patients randomized within the RATIFY trial,...

Cite
Rücker FG, Du L, Luck TJ, et al. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2021;doi: 10.1038/s41375-021-01323-0.
Rücker, F. G., Du, L., Luck, T. J., Benner, A., Krzykalla, J., Gathmann, I., Voso, M. T., Amadori, S., Prior, T. W., Brandwein, J. M., Appelbaum, F. R., Medeiros, B. C., Tallman, M. S., Savoie, L., Sierra, J., Pallaud, C., Sanz, M. A., Jansen, J. H., Niederwieser, D., Fischer, T., Ehninger, G., Heuser, M., Ganser, A., Bullinger, L., Larson, R. A., Bloomfield, C. D., Stone, R. M., Döhner, H., Thiede, C., & Döhner, K. (2021). Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia, . https://doi.org/10.1038/s41375-021-01323-0
Rücker, Frank G, et al. "Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results." Leukemia vol. (2021). doi: https://doi.org/10.1038/s41375-021-01323-0
Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Döhner H, Thiede C, Döhner K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2021 Jul 28; doi: 10.1038/s41375-021-01323-0. Epub 2021 Jul 28. PMID: 34316017.
Copy Download .nbib Format: NLM
Loss-of-Function Mutations of .

Cancers

Eckardt JN, Stasik S, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Stölzel F, Kroschinsky F, Schetelig J, Bornhäuser M, Thiede C, Middeke JM.
PMID: 33926021
Cancers (Basel). 2021 Apr 26;13(9). doi: 10.3390/cancers13092095.

Acute myeloid leukemia (AML) is characterized by recurrent genetic events. The

Cite
Eckardt JN, Stasik S, Kramer M, et al. Loss-of-Function Mutations of . Cancers (Basel). 2021;13(9)doi: 10.3390/cancers13092095.
Eckardt, J. N., Stasik, S., Kramer, M., Röllig, C., Krämer, A., Scholl, S., Hochhaus, A., Crysandt, M., Brümmendorf, T. H., Naumann, R., Steffen, B., Kunzmann, V., Einsele, H., Schaich, M., Burchert, A., Neubauer, A., Schäfer-Eckart, K., Schliemann, C., Krause, S. W., Herbst, R., Hänel, M., Frickhofen, N., Noppeney, R., Kaiser, U., Baldus, C. D., Kaufmann, M., Rácil, Z., Platzbecker, U., Berdel, W. E., Mayer, J., Serve, H., Müller-Tidow, C., Ehninger, G., Stölzel, F., Kroschinsky, F., Schetelig, J., Bornhäuser, M., Thiede, C., & Middeke, J. M. (2021). Loss-of-Function Mutations of . Cancers, 13(9), . https://doi.org/10.3390/cancers13092095
Eckardt, Jan-Niklas, et al. "Loss-of-Function Mutations of ." Cancers vol. 13,9 (2021). doi: https://doi.org/10.3390/cancers13092095
Eckardt JN, Stasik S, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Stölzel F, Kroschinsky F, Schetelig J, Bornhäuser M, Thiede C, Middeke JM. Loss-of-Function Mutations of . Cancers (Basel). 2021 Apr 26;13(9). doi: 10.3390/cancers13092095. PMID: 33926021; PMCID: PMC8123716.
Copy Download .nbib Format: NLM
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.

Blood

Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, Adès L, Lebon D, Malfuson JV, Gastaud L, Goursaud L, Raffoux E, Wattebled KJ, Rousselot P, Thomas X, Chantepie S, Cluzeau T, Serve H, Boissel N, Terré C, Celli-Lebras K, Preudhomme C, Thiede C, Dombret H, Gardin C, Duployez N.
PMID: 34410352
Blood. 2021 Aug 19;138(7):507-519. doi: 10.1182/blood.2021011103.

To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) ≥60 years of age treated with 7 + 3, we sequenced 37 genes in 471 patients from the ALFA1200 (Acute...

Cite
Itzykson R, Fournier E, Berthon C, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507-519doi: 10.1182/blood.2021011103.
Itzykson, R., Fournier, E., Berthon, C., Röllig, C., Braun, T., Marceau-Renaut, A., Pautas, C., Nibourel, O., Lemasle, E., Micol, J. B., Adès, L., Lebon, D., Malfuson, J. V., Gastaud, L., Goursaud, L., Raffoux, E., Wattebled, K. J., Rousselot, P., Thomas, X., Chantepie, S., Cluzeau, T., Serve, H., Boissel, N., Terré, C., Celli-Lebras, K., Preudhomme, C., Thiede, C., Dombret, H., Gardin, C., & Duployez, N. (2021). Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood, 138(7), 507-519. https://doi.org/10.1182/blood.2021011103
Itzykson, Raphael, et al. "Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy." Blood vol. 138,7 (2021): 507-519. doi: https://doi.org/10.1182/blood.2021011103
Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, Adès L, Lebon D, Malfuson JV, Gastaud L, Goursaud L, Raffoux E, Wattebled KJ, Rousselot P, Thomas X, Chantepie S, Cluzeau T, Serve H, Boissel N, Terré C, Celli-Lebras K, Preudhomme C, Thiede C, Dombret H, Gardin C, Duployez N. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021 Aug 19;138(7):507-519. doi: 10.1182/blood.2021011103. PMID: 34410352.
Copy Download .nbib Format: NLM
Dosimetric Impact of the Positional Imaging Frequency for Hypofractionated Prostate Radiotherapy - A Voxel-by-Voxel Analysis.

Frontiers in oncology

Splinter M, Sachpazidis I, Bostel T, Fechter T, Zamboglou C, Thieke C, Jäkel O, Huber PE, Debus J, Baltas D, Nicolay NH.
PMID: 33134166
Front Oncol. 2020 Sep 29;10:564068. doi: 10.3389/fonc.2020.564068. eCollection 2020.

BACKGROUND: To investigate deviations between planned and applied treatment doses for hypofractionated prostate radiotherapy and to quantify dosimetric accuracy in dependence of the image guidance frequency.METHODS: Daily diagnostic in-room CTs were carried out in 10 patients in treatment position...

Cite
Splinter M, Sachpazidis I, Bostel T, et al. Dosimetric Impact of the Positional Imaging Frequency for Hypofractionated Prostate Radiotherapy - A Voxel-by-Voxel Analysis. Front Oncol. 2020;10:564068doi: 10.3389/fonc.2020.564068.
Splinter, M., Sachpazidis, I., Bostel, T., Fechter, T., Zamboglou, C., Thieke, C., Jäkel, O., Huber, P. E., Debus, J., Baltas, D., & Nicolay, N. H. (2020). Dosimetric Impact of the Positional Imaging Frequency for Hypofractionated Prostate Radiotherapy - A Voxel-by-Voxel Analysis. Frontiers in oncology, 10564068. https://doi.org/10.3389/fonc.2020.564068
Splinter, Mona, et al. "Dosimetric Impact of the Positional Imaging Frequency for Hypofractionated Prostate Radiotherapy - A Voxel-by-Voxel Analysis." Frontiers in oncology vol. 10 (2020): 564068. doi: https://doi.org/10.3389/fonc.2020.564068
Splinter M, Sachpazidis I, Bostel T, Fechter T, Zamboglou C, Thieke C, Jäkel O, Huber PE, Debus J, Baltas D, Nicolay NH. Dosimetric Impact of the Positional Imaging Frequency for Hypofractionated Prostate Radiotherapy - A Voxel-by-Voxel Analysis. Front Oncol. 2020 Sep 29;10:564068. doi: 10.3389/fonc.2020.564068. eCollection 2020. PMID: 33134166; PMCID: PMC7550661.
Copy Download .nbib Format: NLM
Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia.

Biomarker research

Kunadt D, Kramer M, Dill C, Altmann H, Wagenführ L, Mohr B, Thiede C, Röllig C, Schetelig J, Bornhäuser M, Schaich M, Stölzel F.
PMID: 32537166
Biomark Res. 2020 Jun 12;8:20. doi: 10.1186/s40364-020-00200-9. eCollection 2020.

BACKGROUND: Lysyl oxidase (LOX) has been described as necessary for premetastatic niche formation in epithelium-derived malignancies and its expression level therefore correlates with risk of metastatic disease and overall survival. However, its role in acute myeloid leukemia (AML) has...

Cite
Kunadt D, Kramer M, Dill C, et al. Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia. Biomark Res. 2020;8:20doi: 10.1186/s40364-020-00200-9.
Kunadt, D., Kramer, M., Dill, C., Altmann, H., Wagenführ, L., Mohr, B., Thiede, C., Röllig, C., Schetelig, J., Bornhäuser, M., Schaich, M., & Stölzel, F. (2020). Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia. Biomarker research, 820. https://doi.org/10.1186/s40364-020-00200-9
Kunadt, Desiree, et al. "Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia." Biomarker research vol. 8 (2020): 20. doi: https://doi.org/10.1186/s40364-020-00200-9
Kunadt D, Kramer M, Dill C, Altmann H, Wagenführ L, Mohr B, Thiede C, Röllig C, Schetelig J, Bornhäuser M, Schaich M, Stölzel F. Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia. Biomark Res. 2020 Jun 12;8:20. doi: 10.1186/s40364-020-00200-9. eCollection 2020. PMID: 32537166; PMCID: PMC7291659.
Copy Download .nbib Format: NLM
The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).

Clinical colorectal cancer

Folprecht G, Reinacher-Schick A, Weitz J, Lugnier C, Kraeft AL, Wisser S, Aust DE, Weiss L, von Bubnoff N, Kramer M, Thiede C, Tannapfel A.
PMID: 34772609
Clin Colorectal Cancer. 2021 Sep 15; doi: 10.1016/j.clcc.2021.09.005. Epub 2021 Sep 15.

BACKGROUND: Guidance regarding adjuvant treatment decisions in stage II colorectal cancer (CRC) remains uncertain due to lack of predictive clinical or molecular markers. Recently, postoperative circulating tumour (ct)DNA has been demonstrated to be a strong prognostic marker in early...

Cite
Folprecht G, Reinacher-Schick A, Weitz J, et al. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). Clin Colorectal Cancer. 2021;doi: 10.1016/j.clcc.2021.09.005.
Folprecht, G., Reinacher-Schick, A., Weitz, J., Lugnier, C., Kraeft, A. L., Wisser, S., Aust, D. E., Weiss, L., von Bubnoff, N., Kramer, M., Thiede, C., & Tannapfel, A. (2021). The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). Clinical colorectal cancer, . https://doi.org/10.1016/j.clcc.2021.09.005
Folprecht, Gunnar, et al. "The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217)." Clinical colorectal cancer vol. (2021). doi: https://doi.org/10.1016/j.clcc.2021.09.005
Folprecht G, Reinacher-Schick A, Weitz J, Lugnier C, Kraeft AL, Wisser S, Aust DE, Weiss L, von Bubnoff N, Kramer M, Thiede C, Tannapfel A. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). Clin Colorectal Cancer. 2021 Sep 15; doi: 10.1016/j.clcc.2021.09.005. Epub 2021 Sep 15. PMID: 34772609.
Copy Download .nbib Format: NLM
Climate Variability and Child Nutrition: Findings from Sub-Saharan Africa.

Global environmental change : human and policy dimensions

Thiede BC, Strube J.
PMID: 34789965
Glob Environ Change. 2020 Nov;65. doi: 10.1016/j.gloenvcha.2020.102192. Epub 2020 Nov 26.

Climatic variability affects many underlying determinants of child malnutrition, including food availability, access, and utilization. Evidence of the effects of changing temperatures and precipitation on children's nutritional status nonetheless remains limited. Research addressing this knowledge gap is merited given...

Cite
Thiede BC, Strube J. Climate Variability and Child Nutrition: Findings from Sub-Saharan Africa. Glob Environ Change. 2020;65doi: 10.1016/j.gloenvcha.2020.102192.
Thiede, B. C., & Strube, J. (2020). Climate Variability and Child Nutrition: Findings from Sub-Saharan Africa. Global environmental change : human and policy dimensions, 65. https://doi.org/10.1016/j.gloenvcha.2020.102192
Thiede, Brian C, and Strube, Johann. "Climate Variability and Child Nutrition: Findings from Sub-Saharan Africa." Global environmental change : human and policy dimensions vol. 65 (2020). doi: https://doi.org/10.1016/j.gloenvcha.2020.102192
Thiede BC, Strube J. Climate Variability and Child Nutrition: Findings from Sub-Saharan Africa. Glob Environ Change. 2020 Nov;65. doi: 10.1016/j.gloenvcha.2020.102192. Epub 2020 Nov 26. PMID: 34789965; PMCID: PMC8594912.
Copy Download .nbib Format: NLM
Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in .

Oncotarget

Garz AK, Wolf S, Grath S, Gaidzik V, Habringer S, Vick B, Rudelius M, Ziegenhain C, Herold S, Weickert MT, Smets M, Peschel C, Oostendorp RAJ, Bultmann S, Jeremias I, Thiede C, Döhner K, Keller U, Götze KS.
PMID: 29312564
Oncotarget. 2017 Oct 16;8(65):108738-108759. doi: 10.18632/oncotarget.21877. eCollection 2017 Dec 12.

Effectively targeting leukemia-initiating cells (LIC) in

Cite
Garz AK, Wolf S, Grath S, et al. Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in . Oncotarget. 2017;8(65):108738-108759doi: 10.18632/oncotarget.21877.
Garz, A. K., Wolf, S., Grath, S., Gaidzik, V., Habringer, S., Vick, B., Rudelius, M., Ziegenhain, C., Herold, S., Weickert, M. T., Smets, M., Peschel, C., Oostendorp, R. A. J., Bultmann, S., Jeremias, I., Thiede, C., Döhner, K., Keller, U., & Götze, K. S. (2017). Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in . Oncotarget, 8(65), 108738-108759. https://doi.org/10.18632/oncotarget.21877
Garz, Anne-Kathrin, et al. "Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in ." Oncotarget vol. 8,65 (2017): 108738-108759. doi: https://doi.org/10.18632/oncotarget.21877
Garz AK, Wolf S, Grath S, Gaidzik V, Habringer S, Vick B, Rudelius M, Ziegenhain C, Herold S, Weickert MT, Smets M, Peschel C, Oostendorp RAJ, Bultmann S, Jeremias I, Thiede C, Döhner K, Keller U, Götze KS. Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in . Oncotarget. 2017 Oct 16;8(65):108738-108759. doi: 10.18632/oncotarget.21877. eCollection 2017 Dec 12. PMID: 29312564; PMCID: PMC5752477.
Copy Download .nbib Format: NLM
Regulation of bi-directional movement of single kinesin-5 Cin8 molecules.

Bioarchitecture

Thiede C, Fridman V, Gerson-Gurwitz A, Gheber L, Schmidt CF.
PMID: 22754632
Bioarchitecture. 2012 Feb 01;2(2):70-74. doi: 10.4161/bioa.20395.

Kinesin-5 mechanoenzymes drive mitotic spindle dynamics as slow, processive microtubule (MT)-plus-end directed motors. Surprisingly, the Saccharomyces cerevisiae kinesin-5 Cin8 was recently found to be bi-directional: it can move processively in both directions on MTs. Two hypotheses have been suggested...

Cite
Thiede C, Fridman V, Gerson-Gurwitz A, et al. Regulation of bi-directional movement of single kinesin-5 Cin8 molecules. Bioarchitecture. 2012;2(2):70-74doi: 10.4161/bioa.20395.
Thiede, C., Fridman, V., Gerson-Gurwitz, A., Gheber, L., & Schmidt, C. F. (2012). Regulation of bi-directional movement of single kinesin-5 Cin8 molecules. Bioarchitecture, 2(2), 70-74. https://doi.org/10.4161/bioa.20395
Thiede, Christina, et al. "Regulation of bi-directional movement of single kinesin-5 Cin8 molecules." Bioarchitecture vol. 2,2 (2012): 70-74. doi: https://doi.org/10.4161/bioa.20395
Thiede C, Fridman V, Gerson-Gurwitz A, Gheber L, Schmidt CF. Regulation of bi-directional movement of single kinesin-5 Cin8 molecules. Bioarchitecture. 2012 Feb 01;2(2):70-74. doi: 10.4161/bioa.20395. PMID: 22754632; PMCID: PMC3383724.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 57 entries